UroGen Pharma Ltd. (URGN)
Develops targeted cancer treatments delivered directly into the bladder and urinary tract.
$40.88-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+110.7%
The outlook
URGN is trading near the upper end of its 52-week range, well above both its 50- and 200-day moving averages. Analysts strongly favor the stock with an average rating of Strong Buy, and their price target sits roughly 9% above the current level. The overall sentiment is decidedly bullish based on recent technical positioning and analyst coverage.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range89% of the way from its 52-week low to high
Price targetAvg target +9% vs current price
Analyst price target
~12-month · 8 analysts$44.75average target+9.5% vs now
Now $40.88
Low $40.00High $50.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.99B
52-wk high
$43.93
52-wk low
$15.86
50-day avg
$33.85
200-day avg
$24.62
Trailing P/E
—